Protein Kinase Inhibitors: all 15,278 studies that test it

Page 92 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic MalignanciesTerminatedNCT04504708Phase 1/2
• Dacomitinib in Lung Cancer With Uncommon EGFR MutationsActive, not recruitingNCT04504071Phase 2
• Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal CancerStatus unknownNCT04503967Phase 2
• Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04503902Phase 1/2
• Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal CancerActive, not recruitingNCT04503694Phase 2
• Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian CancerActive, not recruitingNCT04502602Phase 1
• Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring OxygenWithdrawnNCT04502069Phase 1/2
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene MutationStatus unknownNCT04500717Phase 3
• Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLCStatus unknownNCT04500704Phase 3
• YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical TrialStatus unknownNCT04500561Phase 1/2
• Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnNCT04498520Phase 1
• Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLCActive, not recruitingNCT04497584Phase 2
• Selumetinib Paediatric NF1 Japan StudyCompletedNCT04495127Phase 1
• A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on FamitinibCompletedNCT04494659Phase 1
• A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male ParticipantsCompletedNCT04493255Phase 1
• Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsActive, not recruitingNCT04493138Phase 1/2
• Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AMLWithdrawnNCT04493099Phase 1/2
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerActive, not recruitingNCT04491942Phase 1
• TACE Combined With Lenvatinib for Unresectable Hepatocellular CarcinomaStatus unknownNCT04490694Phase 2
• A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy ParticipantsCompletedNCT04489797Phase 1
• Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity StudyCompletedNCT04488601Phase 2
• Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437cStatus unknownNCT04488107Phase 1/2
• I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingNCT04488081Phase 2
• A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical CancerActive, not recruitingNCT04487587Phase 2
• Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid TumorsCompletedNCT04487236Phase 1
• Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II TrialActive, not recruitingNCT04486911Phase 2
• Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA PatientsCompletedNCT04485325Phase 4
• Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT04484012Phase 2
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drug TherapyWithdrawnNCT04483700Phase 3
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug TherapyWithdrawnNCT04483687Phase 3
• Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDSWithdrawnNCT04482712Phase 1/2
• A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing SpondylitisCompletedNCT04481139Phase 2/3
• Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast CancerCompletedNCT04481113Phase 1
• A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic CholangiocarcinomaWithdrawnNCT04479904Phase 2
• Effect of Itraconazole on the Pharmacokinetics of Pyrotinib in Healthy SubjectsCompletedNCT04479891Phase 1
• Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerCompletedNCT04479306Phase 1
• Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19TerminatedNCT04477993Phase 2/3
• Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)CompletedNCT04477512Phase 1
• A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDSTerminatedNCT04477291Phase 1
• PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid TumorsStatus unknownNCT04477057Phase 1
• Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLStatus unknownNCT04476459Phase 1/2
• Optimization for Regorafenib in HCCTerminatedNCT04476329Phase 2
• Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological RelapseActive, not recruitingNCT04475731Phase 2
• Haplo Peripheral Blood Sct In GVHD PreventionCompletedNCT04473911Phase 1
• Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCACompletedNCT04470804Phase 4
• Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma SubtypeCompletedNCT04470726Phase 1/2
• A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell LymphomaStatus unknownNCT04470141Phase 2
• Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating MutationStatus unknownNCT04470076Phase 2
• A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19CompletedNCT04469621Phase 1
• Tofacitinib in Hospitalized Patients With COVID-19 PneumoniaCompletedNCT04469114Phase 3
• Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory MyelofibrosisActive, not recruitingNCT04468984Phase 3
• Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging StudyCompletedNCT04468425Phase 1
• A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029CompletedNCT04466514Phase 1
• Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid ArthritisStatus unknownNCT04464642Phase 4
• The Absorption, Metabolism and Excretion of [14C]D-0316 in HumanStatus unknownNCT04464551Phase 1
• Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's MacroglobulinemiaCompletedNCT04463953Phase 2
• Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid TumoursCompletedNCT04462952Phase 1
• Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIbCompletedNCT04462445Phase 2
• Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System LymphomaActive, not recruitingNCT04462328Phase 1
• Efficacy and Safety of Sirolimus in COVID-19 InfectionStatus unknownNCT04461340Phase 2
• A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain MetastasesWithdrawnNCT04460729Phase 2
• Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast CancerTerminatedNCT04460430Phase 2
• Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
• Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung AdenocarcinomaStatus unknownNCT04459078Phase 2
• Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT04458610Phase 2
• Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)CompletedNCT04458051Phase 3
• T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD TrialActive, not recruitingNCT04457596Phase 3
• A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor SubjectsCompletedNCT04457180Phase 1
• A Phase I Study of SHR1459 in Healthy SubjectsCompletedNCT04455100Phase 1
• A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver FunctionStatus unknownNCT04454762Phase 2
• A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）Status unknownNCT04453930Phase 2
• Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.Status unknownNCT04453423Phase 2
• Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast CancerStatus unknownNCT04452370Phase 2
• Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal CancerTerminatedNCT04450836Phase 2
• Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular LymphomaActive, not recruitingNCT04450173Phase 2
• Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform HemangioendotheliomaCompletedNCT04448873Phase 4
• A Clinical Trial to Evaluate the Effect of Nilotinib on the PK/PD of MeforminCompletedNCT04448821Phase 1
• A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPSStatus unknownNCT04447274Phase 2
• Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based ChemotherapyCompletedNCT04447118Phase 3
• LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)Active, not recruitingNCT04446962Phase 1/2
• Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic LeukemiaStatus unknownNCT04446806Phase 4
• A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Active, not recruitingNCT04446650Phase 1/2
• Evaluation of GLR2007 for Advanced Solid TumorsCompletedNCT04444427Phase 1/2
• Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial CarcinomaStatus unknownNCT04444193Not applicable
• Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCCStatus unknownNCT04443309Phase 1/2
• ADME Study of [14C]ICP-022 in Healthy MalesCompletedNCT04441450Not applicable
• Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell CarcinomaStatus unknownNCT04440917Phase 2
• A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom MacroglobulinemiaCompletedNCT04440059Phase 2
• A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung CancerStatus unknownNCT04439890Phase 3
• Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
• Ibrutinib for the Treatment of COVID-19 in Patients Requiring HospitalizationCompletedNCT04439006Phase 1
• Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib TreatmentTerminatedNCT04438902Phase 2
• A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSLStatus unknownNCT04438044Phase 2
• A Study of ICP-022 in Patients With R/R DLBCLCompletedNCT04438005Phase 2
• Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male SubjectsCompletedNCT04436562Phase 1
• Efficacy and Safety of Cabozantinib in Patients With Hepatocellular CarcinomaStatus unknownNCT04435977Phase 2
• The Absorption, Metabolism and Excretion of [14C]CM082 in HumanCompletedNCT04434326Phase 1
• Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell LymphomaTerminatedNCT04433182Phase 2
• Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot StudyCompletedNCT04431895Early Phase 1

← Protein Kinase Inhibitors overview